Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103375251> ?p ?o ?g. }
- W2103375251 endingPage "416" @default.
- W2103375251 startingPage "406" @default.
- W2103375251 abstract "Background The prevalence of non-alcoholic fatty liver disease is increasing worldwide and an effective and safe pharmacological treatment is needed. We investigated whether inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1, also known as HSD11B1) by RO5093151 could safely and effectively decrease liver-fat content in patients with this disorder. Methods We did this phase 1b trial at four centres in Germany and Austria. Participants with non-alcoholic fatty liver disease (defined as 1H magnetic resonance spectroscopy liver-fat content >5·56%), insulin resistance (homoeostatic model assessment of insulin resistance [HOMA-IR] of at least 2·0 mmol/L·mU/L), BMI greater than 27 kg/m2, and aged 35–65 years were randomly assigned by interactive voice response system in a 1:1 ratio, stratified for triglyceride concentration (<1·7 mmol/L or ≥1·7 mmol/L), to oral RO5093151 (200 mg twice daily) or matching placebo for 12 weeks. The main exclusion criteria were other liver diseases, aspartate aminotransferase or alanine aminotransferase concentrations of more than two and a half times the upper limit of normal, history of diabetes or bariatric surgery, and use of weight lowering drugs. Participants and investigators were masked to assignment throughout the study. The primary endpoint was change in liver-fat content from baseline to week 12. Efficacy analysis was by modified intention to treat, including all patients who received at least one dose of study drug and had a baseline and follow-up measurement of liver-fat content. Safety analyses included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT01277094. Findings We did this trial between Jan 13, 2011, and March 28, 2012. 41 patients were randomly assigned to RO5093151 and 41 to placebo. 35 patients in the RO5093151 group and 39 in the placebo group were included in the efficacy analysis. Mean liver-fat content decreased in the RO5093151 group (from 16·75% [SD 8·67] to 14·28% [8·89]), but not in the placebo group (from 18·53% [10·00] to 18·46% [10·78], p=0·02 for between group difference). 26 participants (65%) in the RO5093151 group had adverse events, compared with 21 (53%) in the placebo group. The most common adverse events were gastrointestinal disorders (12 patients [30%] in the RO5093151 group vs seven [18%] in the placebo group), and infections and infestations (eight [20%] vs nine [23%]). Nervous system disorders occurred in significantly more patients in the RO5093151 group than in the placebo group (nine [23%] vs two [5%]; p=0·02); all other differences in adverse events were non-significant. One participant (3%) in the placebo group and three participants (8%) in the RO5093151 group had serious adverse events. All serious adverse events were deemed unrelated to study treatment. Interpretation Inhibition of 11β-HSD1 by RO5093151 was effective and safe in reducing liver-fat content, suggesting that targeting of 11β-HSD1 might be a promising approach for the treatment of non-alcoholic fatty liver disease. Funding F Hoffmann-La Roche. The prevalence of non-alcoholic fatty liver disease is increasing worldwide and an effective and safe pharmacological treatment is needed. We investigated whether inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1, also known as HSD11B1) by RO5093151 could safely and effectively decrease liver-fat content in patients with this disorder. We did this phase 1b trial at four centres in Germany and Austria. Participants with non-alcoholic fatty liver disease (defined as 1H magnetic resonance spectroscopy liver-fat content >5·56%), insulin resistance (homoeostatic model assessment of insulin resistance [HOMA-IR] of at least 2·0 mmol/L·mU/L), BMI greater than 27 kg/m2, and aged 35–65 years were randomly assigned by interactive voice response system in a 1:1 ratio, stratified for triglyceride concentration (<1·7 mmol/L or ≥1·7 mmol/L), to oral RO5093151 (200 mg twice daily) or matching placebo for 12 weeks. The main exclusion criteria were other liver diseases, aspartate aminotransferase or alanine aminotransferase concentrations of more than two and a half times the upper limit of normal, history of diabetes or bariatric surgery, and use of weight lowering drugs. Participants and investigators were masked to assignment throughout the study. The primary endpoint was change in liver-fat content from baseline to week 12. Efficacy analysis was by modified intention to treat, including all patients who received at least one dose of study drug and had a baseline and follow-up measurement of liver-fat content. Safety analyses included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT01277094. We did this trial between Jan 13, 2011, and March 28, 2012. 41 patients were randomly assigned to RO5093151 and 41 to placebo. 35 patients in the RO5093151 group and 39 in the placebo group were included in the efficacy analysis. Mean liver-fat content decreased in the RO5093151 group (from 16·75% [SD 8·67] to 14·28% [8·89]), but not in the placebo group (from 18·53% [10·00] to 18·46% [10·78], p=0·02 for between group difference). 26 participants (65%) in the RO5093151 group had adverse events, compared with 21 (53%) in the placebo group. The most common adverse events were gastrointestinal disorders (12 patients [30%] in the RO5093151 group vs seven [18%] in the placebo group), and infections and infestations (eight [20%] vs nine [23%]). Nervous system disorders occurred in significantly more patients in the RO5093151 group than in the placebo group (nine [23%] vs two [5%]; p=0·02); all other differences in adverse events were non-significant. One participant (3%) in the placebo group and three participants (8%) in the RO5093151 group had serious adverse events. All serious adverse events were deemed unrelated to study treatment. Inhibition of 11β-HSD1 by RO5093151 was effective and safe in reducing liver-fat content, suggesting that targeting of 11β-HSD1 might be a promising approach for the treatment of non-alcoholic fatty liver disease." @default.
- W2103375251 created "2016-06-24" @default.
- W2103375251 creator A5000751030 @default.
- W2103375251 creator A5005286770 @default.
- W2103375251 creator A5011001304 @default.
- W2103375251 creator A5015192785 @default.
- W2103375251 creator A5022032933 @default.
- W2103375251 creator A5022174704 @default.
- W2103375251 creator A5022372898 @default.
- W2103375251 creator A5026711776 @default.
- W2103375251 creator A5028621975 @default.
- W2103375251 creator A5039452695 @default.
- W2103375251 creator A5048083486 @default.
- W2103375251 creator A5049482906 @default.
- W2103375251 creator A5050877182 @default.
- W2103375251 creator A5054433148 @default.
- W2103375251 creator A5059171474 @default.
- W2103375251 creator A5070639714 @default.
- W2103375251 creator A5073351502 @default.
- W2103375251 creator A5084404405 @default.
- W2103375251 date "2014-05-01" @default.
- W2103375251 modified "2023-10-16" @default.
- W2103375251 title "Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial" @default.
- W2103375251 cites W1965576057 @default.
- W2103375251 cites W1966749022 @default.
- W2103375251 cites W1970765180 @default.
- W2103375251 cites W1990055069 @default.
- W2103375251 cites W1997757017 @default.
- W2103375251 cites W2019280401 @default.
- W2103375251 cites W2034531865 @default.
- W2103375251 cites W2060371641 @default.
- W2103375251 cites W2062812115 @default.
- W2103375251 cites W2065612971 @default.
- W2103375251 cites W2069412892 @default.
- W2103375251 cites W2071749236 @default.
- W2103375251 cites W2078349405 @default.
- W2103375251 cites W2092020543 @default.
- W2103375251 cites W2103156933 @default.
- W2103375251 cites W2106061083 @default.
- W2103375251 cites W2119251936 @default.
- W2103375251 cites W2129546749 @default.
- W2103375251 cites W2136226749 @default.
- W2103375251 cites W2146575585 @default.
- W2103375251 cites W2150925908 @default.
- W2103375251 cites W2151901526 @default.
- W2103375251 cites W2153461284 @default.
- W2103375251 cites W2156597872 @default.
- W2103375251 cites W2159469729 @default.
- W2103375251 cites W2160234571 @default.
- W2103375251 cites W2166568789 @default.
- W2103375251 cites W2316193238 @default.
- W2103375251 cites W4233562854 @default.
- W2103375251 cites W4376849750 @default.
- W2103375251 cites W63938293 @default.
- W2103375251 doi "https://doi.org/10.1016/s2213-8587(13)70170-0" @default.
- W2103375251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24795254" @default.
- W2103375251 hasPublicationYear "2014" @default.
- W2103375251 type Work @default.
- W2103375251 sameAs 2103375251 @default.
- W2103375251 citedByCount "90" @default.
- W2103375251 countsByYear W21033752512014 @default.
- W2103375251 countsByYear W21033752512015 @default.
- W2103375251 countsByYear W21033752512016 @default.
- W2103375251 countsByYear W21033752512017 @default.
- W2103375251 countsByYear W21033752512018 @default.
- W2103375251 countsByYear W21033752512019 @default.
- W2103375251 countsByYear W21033752512020 @default.
- W2103375251 countsByYear W21033752512021 @default.
- W2103375251 countsByYear W21033752512022 @default.
- W2103375251 countsByYear W21033752512023 @default.
- W2103375251 crossrefType "journal-article" @default.
- W2103375251 hasAuthorship W2103375251A5000751030 @default.
- W2103375251 hasAuthorship W2103375251A5005286770 @default.
- W2103375251 hasAuthorship W2103375251A5011001304 @default.
- W2103375251 hasAuthorship W2103375251A5015192785 @default.
- W2103375251 hasAuthorship W2103375251A5022032933 @default.
- W2103375251 hasAuthorship W2103375251A5022174704 @default.
- W2103375251 hasAuthorship W2103375251A5022372898 @default.
- W2103375251 hasAuthorship W2103375251A5026711776 @default.
- W2103375251 hasAuthorship W2103375251A5028621975 @default.
- W2103375251 hasAuthorship W2103375251A5039452695 @default.
- W2103375251 hasAuthorship W2103375251A5048083486 @default.
- W2103375251 hasAuthorship W2103375251A5049482906 @default.
- W2103375251 hasAuthorship W2103375251A5050877182 @default.
- W2103375251 hasAuthorship W2103375251A5054433148 @default.
- W2103375251 hasAuthorship W2103375251A5059171474 @default.
- W2103375251 hasAuthorship W2103375251A5070639714 @default.
- W2103375251 hasAuthorship W2103375251A5073351502 @default.
- W2103375251 hasAuthorship W2103375251A5084404405 @default.
- W2103375251 hasConcept C126322002 @default.
- W2103375251 hasConcept C134018914 @default.
- W2103375251 hasConcept C142724271 @default.
- W2103375251 hasConcept C203092338 @default.
- W2103375251 hasConcept C204787440 @default.
- W2103375251 hasConcept C27081682 @default.
- W2103375251 hasConcept C2775934546 @default.
- W2103375251 hasConcept C2777180221 @default.
- W2103375251 hasConcept C2777214474 @default.